Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) announced 11 poster presentations showcasing Tumor Treating Fields (TTFields) at the ASTRO 2022 Annual Meeting, scheduled from Oct. 23-26 in San Antonio, Texas. The data highlights the efficacy of TTFields in newly diagnosed glioblastoma and its potential in conjunction with therapies like PARP and PI3K inhibitors. Notable studies will include investigations into biomarkers influencing survival rates and synergistic effects with other cancer treatments. This presentation underlines Novocure's commitment to advancing cancer treatment.
- 11 poster presentations on Tumor Treating Fields at ASTRO 2022.
- Pre-clinical research indicates enhanced tumor control when TTFields are combined with PULSAR, PARP inhibitors, and PI3K inhibitors.
- Positive outcomes from studies on predictive biomarkers for glioblastoma.
- None.
Highlights include an analysis of predictive biomarkers for overall survival and progression free survival in newly diagnosed glioblastoma patients
Pre-clinical research shows the potential for improved tumor control when Tumor Treating Fields are used with PULSAR in glioblastoma, PARP inhibitors in ovarian cancer and PI3K inhibitors in non-small cell lung cancer, GBM and ovarian cancer
ROOT,
TTFields are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields therapy has multiple mechanisms of action that can impact cancer cell division, disrupt cancer cell DNA damage repair, promote anti-cancer immunity, and interfere with cancer cell motility, making cancer cells more susceptible to different therapeutics.
New research includes positive results from a pre-clinical evaluation of personalized ultra-fractionated stereotactic adaptive radiotherapy (PULSAR) with TTFields resulting in delays in tumor growth. Other pre-clinical research showed positive outcomes demonstrating that use of TTFields concurrently with other novel targeted therapies, such as PI3K and PARP inhibitors, has the potential for a therapeutic advantage. Clinical trials continue to investigate biomarkers predictive for survival in newly diagnosed glioblastoma (GBM).
“We are encouraged by the data in GBM, ovarian cancer and non-small cell lung cancer, demonstrating the effects of Tumor Treating Fields in some of the most difficult to treat solid tumors where patients have limited treatment options,” said
The following will be presented at the ASTRO 2022 Annual Meeting:
Poster Presentations
Clinical Studies
(2149) Chemoradiation treatment with or without concurrent Tumor-Treating Fields (TTFields) in patients with newly diagnosed glioblastoma (GBM). Lead author and presenter:
(2150) Molecular markers impacting survival in patients receiving concurrent chemoradiation and Tumor-Treating Fields (TTF) in patients with newly diagnosed glioblastoma: secondary analysis of SPARE trial. Lead author and presenter:
(2152) A propensity-matched study to evaluate PTEN and TP53 mutations as predictive biomarkers of survival in newly diagnosed IDH-wildtype glioblastoma after Tumor Treating Fields. Lead author and presenter:
Pre-Clinical Studies
(2154) Tumor Treating Fields (TTFields) enhance the efficacy of temozolomide and lomustine in glioblastoma cell lines. Lead author:
(3164) Enhancing cancer cell membrane permeability by application of Tumor Treating Fields (TTFields). Lead author:
(3165) Tumor Treating Fields (TTFields) delivery to macrophages promotes a pro-inflammatory phenotype. Lead author:
(3169) Preclinical evaluation of Tumor Treating Fields Combined with Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR). Lead author:
(2618) Tumor Treating Fields (TTFields) concomitant with PARP inhibitors for treatment of ovarian cancer cell lines. Lead author:
(2619) PI3K Inhibition sensitized cancerous cells to Tumor Treating Fields (TTFields). Lead author:
Dose Distribution Simulations
(3300) Examining array layouts for targeting a single lung with TTFields. Lead author and presenter:
(3233) Sensitivity of TTFields dose distribution in the lungs to the deviations in array placement. Lead author and presenter:
All poster presentations are located in
About Tumor Treating Fields
Tumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. The multiple, distinct mechanisms of TTFields therapy work together to selectively target and kill cancer cells. Due to its multi-mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibition, or PARP inhibition in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about Tumor Treating Fields therapy and its multifaceted effect on cancer cells, visit tumortreatingfieldstherapy.com.
About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Headquartered in Root,
Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on
View source version on businesswire.com: https://www.businesswire.com/news/home/20221021005493/en/
Investors:
investorinfo@novocure.com
610-723-7427
Media:
media@novocure.com
610-723-7428
Source: Novocure
FAQ
What are the main findings from Novocure's research presented at ASTRO 2022?
When is the ASTRO 2022 Annual Meeting where Novocure will present?
What is the significance of Tumor Treating Fields in cancer treatment according to Novocure?
Which cancers are being studied with Tumor Treating Fields according to the press release?